公开(公告)号：US20200179303A1

公开(公告)日：2020-06-11

申请号：US16791940

申请日：2020-02-14

申请人： GW Research Limited

发明人： Geoffrey GUY ,  Stephen WRIGHT ,  Alice MEAD ,  Orrin DEVINSKY

IPC分类号： A61K31/05 ,  A61K31/55 ,  A61K31/515 ,  A61K31/444 ,  A61K9/08 ,  A61K9/00 ,  A61K47/44 ,  A61K47/26 ,  A61K47/10 ,  A61K31/36 ,  A61K31/35 ,  A61K31/197 ,  A61K31/19 ,  A61K31/165 ,  A61K45/06 ,  A61K36/185 ,  A61K31/7048 ,  A61K31/5517 ,  A61K31/5513 ,  A61K31/551 ,  A61K31/53 ,  A61K31/496 ,  A61K31/423 ,  A61K31/4166 ,  A61K31/4015 ,  A61K31/352 ,  A61K31/27 ,  A61K31/20 ,  A61K31/195

摘要： The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

公开(公告)号：US10588979B1

公开(公告)日：2020-03-17

申请号：US16133572

申请日：2018-09-17

申请人： Cody D. Freeze ,  Allison N. Freeze

发明人： Cody D. Freeze ,  Allison N. Freeze

IPC分类号： A61K31/047 ,  A61K47/46 ,  A61K9/00 ,  A61K9/06 ,  A61K47/22 ,  A61K47/10 ,  A61K45/06 ,  A61K47/24 ,  A61K31/352 ,  A61K31/045 ,  A61K31/11 ,  A61K31/122 ,  A61K31/35 ,  A61K47/18

摘要： The present invention discloses a topical composition comprising terpene blend and cannabidiol (CBD) or a derivative thereof, useful for managing pain, the treatment or prevention of inflammatory skin disorders, and treatment methods thereof. The composition includes 2-pyrrolidone-5-carboxylic acid and a blend of antioxidants to optimize tissue health.

公开(公告)号：US20200069591A1

公开(公告)日：2020-03-05

申请号：US16467922

申请日：2017-11-30

申请人： BAYER ANIMAL HEALTH GMBH

发明人： Venkata-Rangarao KANIKANTI ,  Patrick BILLIAN

IPC分类号： A61K9/24 ,  A61K31/27 ,  A61K31/35 ,  A61K31/4985 ,  A61K31/506 ,  A61K9/20

摘要： A solid pharmaceutical preparation The present invention refers to a pharmaceutical preparation (10) comprising a first pharmaceutical composition having a matrix material and pharmaceutically active ingredients distributed within the matrix material, wherein the first pharmaceutical composition comprises Praziquantel, Pyrantel and Febantel as pharmaceutical active ingredients, wherein the preparation (10) comprises a second pharmaceutical composition having a matrix material and at least one of avermectins and milbemycins such as Moxidectin as pharmaceutically active ingredient distributed within the matrix material, wherein the preparation (10) is provided in a multi-layer structure such, that the first composition is provided in a first layer (12) and the second composition is provided in a second layer (14), wherein the first layer (12) and the second layer (14) are separated by a barrier layer (16) being provided between the first layer (12) and the second layer (14).

公开(公告)号：US20190388385A1

公开(公告)日：2019-12-26

申请号：US16508019

申请日：2019-07-10

申请人： Respivant Sciences GmbH

发明人： Pravin Soni ,  William Gerhart ,  Ahmet Tutuncu

IPC分类号： A61K31/352 ,  A61K9/00 ,  A61K31/35

摘要： Methods for the treatment of systemic mast cell related disorders treatable with mast cell stabilizers, including mast well related disorders, are provided.

公开(公告)号：US20190350866A1

公开(公告)日：2019-11-21

申请号：US16220269

申请日：2018-12-14

申请人： Vivus, Inc.

发明人： Thomas NAJARIAN ,  Peter Y. TAM ,  Leland F. WILSON

IPC分类号： A61K9/50 ,  A61K31/357 ,  A61K9/28 ,  A61K31/35 ,  A61K31/137 ,  A61K9/48 ,  A61K31/7048

摘要： A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.

公开(公告)号：US20190336605A1

公开(公告)日：2019-11-07

申请号：US16514066

申请日：2019-07-17

申请人： Immunolight, LLC.

发明人： Frederic A. BOURKE, JR.

IPC分类号： A61K41/00 ,  A61K31/37 ,  A61F7/00 ,  A61K45/06 ,  A61K31/35 ,  A61K31/714 ,  A61N5/06 ,  A61H23/00 ,  A61K31/366 ,  A61N2/02 ,  A61K47/02 ,  A61N5/10

摘要： Methods for the treatment of a cell proliferation disorder in a subject, involving: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of effecting a predetermined cellular change when activated, either alone or in combination with at least one energy modulation agent; and (2) applying an initiation energy from an initiation energy source to the subject, wherein the applying activates the activatable agent in situ, thus causing the predetermined cellular change to occur, wherein the predetermined cellular change treats the cell proliferation disorder, preferably by causing an increase or decrease in rate of cell proliferation, and a kit for performing the method, a computer implemented system for performing the method, a pharmaceutical composition useful in the method and a method for causing an autovaccine effect in a subject using the method.

公开(公告)号：US10456409B2

公开(公告)日：2019-10-29

申请号：US16279421

申请日：2019-02-19

申请人： Nostopharma, LLC

发明人： Ekaterina Vert-Wong

IPC分类号： A61K31/165 ,  A61K31/593 ,  A61K31/35 ,  A23L33/155 ,  C12N5/077 ,  C12N5/0775 ,  A61K45/06 ,  A61K31/22 ,  A61K31/366 ,  A61K31/40 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/47 ,  A61K31/505

摘要： The present invention is directed to compositions and methods for the prevention or treatment of treatment of heterotopic ossification, vascular calcification, or pathologic calcification.

公开(公告)号：US10450348B2

公开(公告)日：2019-10-22

申请号：US15034948

申请日：2014-11-06

申请人： Norwegian University of Science and Technology

发明人： Marit Otterlei ,  Siri Bachke

IPC分类号： A01N37/18 ,  A61K38/00 ,  A61P31/04 ,  A61K38/04 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  C07K14/00 ,  A61K38/17 ,  A01N25/08 ,  A01N63/02 ,  A61K31/165 ,  A61K31/35 ,  A61K31/397 ,  A61K31/43 ,  A61K31/496 ,  A61K31/7036 ,  A61K31/7048 ,  A61K38/14 ,  A61K38/16 ,  A61K41/00 ,  A61K45/06 ,  A61L2/10 ,  A61L2/16

摘要： The present invention provides an agent, or a composition containing an agent, for use in treating or preventing a bacterial infection in a subject, wherein said agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X1X2X3X4X5 (SEQ ID NO: 1) and wherein: X1 is a basic amino acid; X2 is an aromatic amino acid; X3 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X4 is any amino acid other than Proline (P), an acidic amino acid or an aromatic amino acid; and X5 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprising a sequence encoding the oligopeptidic compound of (i). In certain aspects the agent and compositions of the invention may be used as single agents. In other aspects of the invention agents and compositions of the invention may be used in conjunction with one or more additional active agents, such as antibiotics.

公开(公告)号：US20190307722A1

公开(公告)日：2019-10-10

申请号：US16340346

申请日：2017-10-20

申请人： UNIVERSITE CLAUDE BERNARD LYON 1 ,  INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

发明人： Manuel ROSA-CALATRAVA ,  Olivier TERRIER ,  Anaïs PROUST ,  Vincent MOULES

IPC分类号： A61K31/353 ,  A61K31/4375 ,  A61K31/35 ,  A61K9/00 ,  A61K31/7056 ,  A61K38/21 ,  A61P31/14

摘要： The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.

公开(公告)号：US20190298697A1

公开(公告)日：2019-10-03

申请号：US16410110

申请日：2019-05-13

申请人： GALECTO BIOTECH AB

发明人： Lise GRAVELLE ,  Anders PEDERSEN

IPC分类号： A61K31/4192 ,  A61K31/70 ,  A61K31/35 ,  A61K9/00 ,  C07H1/00 ,  A61P9/00 ,  C07H19/056 ,  A61P11/00

摘要： A process for preparing an amorphous form of a compound of formula (I) This amorphous compound I is particularly suitable in treating IPF by pulmonary administration.